Curaleaf International Launches Second Medical Cannabis Flower Product for UK Market

1.7 min readPublished On: July 30th, 2021By

LONDON–Curaleaf International (formerly EMMAC Life Sciences Group), Europe’s largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market. The new products are being manufactured in the UK and will be an extension to Curaleaf International’s existing range of medical cannabis flower and oil products. Curaleaf International’s vertically integrated business model, comprising cultivation, extraction, production and distribution, has been designed so that high quality medical cannabis flower is consistently accessible and affordable for UK patients.

Antonio Costanzo, CEO of Curaleaf International, commented: “We are very pleased to extend our range of medical cannabis products for the UK market. As a market leader, Curaleaf International is focused on solving the key patient and physician challenges relating to the price, accessibility, and sustainability of medical cannabis products. Our vertically integrated supply chain and GMP manufacturing facilities here in the UK allow us to scale rapidly to meet growing patient demand.”

The medical cannabis products are manufactured at Rokshaw, EMMAC’s leading UK Specials Manufacturer. To date, Rokshaw has manufactured more than 9,000 medical formulations for more than 2,600 NHS and private pharmacies and hospitals across the United Kingdom. EMMAC Life Sciences Group acquired Rokshaw in April 2019 and is the Group’s second EU-GMP-certified laboratory.


All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of Curaleaf International. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News